The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of
After much deliberation, the FDA has granted accelerated approval for Biogen’s tofersen for an ultra-rare form of the neurodegenerative disease amyotrophic lateral scleros
Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera
Novartis revealed this morning that it has decided to trim back its R&D pipeline by around 10% to 136 projects, as it continues its transition into a pure-play innovat
The biopharma industry has lost another leading figure with the passing of Andy Zoltners, co-founder of ZS Associates, on the 40th anniversary of the company.
Senior lawmakers in the US across both sides of the political divide have released a list of measures that they are considering to reduce medicine costs for patients and t